Chinese Biopharmaceutical Association Successfully Holds 16th Annual Conference

POTOMAC, Md., June 30, 2011 /PRNewswire/ -- The Chinese Biopharmaceutical Association-USA (CBA) successfully held its 16^th Annual Conference on June 26 in Maryland, US.  

With the theme of From Personal Genomes to Translational Medicine, the conference drew nearly 500 attendees with more than 30 distinguished speakers. Many sponsors supported and exhibited at the conference, including Chinese leading biotech parks, international pharmaceutical and biotech companies, US and Chinese government agencies, and international non-profit organizations.

Mr. Xiongfeng Chen, Counselor and Consul General of the Embassy of People's Republic of China in the USA, attended the conference. In his opening remarks, Mr. Chen recognized CBA’s contributions in promoting scientific communications and collaborations between the US and China, and encouraged the CBA to continue to serve as a bridge between the US and Chinese biopharmaceutical industries. He noted that China will spend $308 billion on science and technology by the end of 2015, and he believes the vast investment will further enhance scientific collaboration between the US and China.

During the conference, Zhifeng Long, PhD, CBA president (2011-2012), chairperson of the conference organizing committee, presented 2011 CBA Brilliant Achievement Award to Mr. Thomas Watkins, President and CEO, Human Genome Sciences Inc, and Jonathan M. Rothberg, PhD, Founder, CEO and Chairman, Ion Torrent Corporation, in recognition of their seminal contributions to science, technology or business development in the biopharmaceutical fields, and their efforts in promoting public awareness of the importance of collaborations between basic and applied researchers, between academia and industry, and between researchers and entrepreneurs.

Dr Long also presented the 2011 CBA Outstanding Public Service Award to Yuling Li, PhD, former CBA president (2007-2008), Fellow at Bioprocess Chemistry, MedImmune, in appreciation of her long-term contribution to the growth of the CBA, her dedication in promoting CBA members’ career advancement, and her long-lasting efforts in carrying out CBA’s mission of facilitating collaboration between biopharmaceutical professionals and promoting global business collaboration in biopharmaceutical fields.

CBA also held its annual election for president-elect during the conference. Richard Y. Zhao, PhD, professor of pathology, Microbiology-Immunology and Human Virology, University of Maryland School of Medicine, was elected CBA’s new president-elect (2011-2012). According to CBA’s bylaws, Dr Zhifeng Long becomes CBA’s president (2011-2012) and Dr Sujuan Ba becomes CBA’s immediate-past president after the annual conference.

In his inaugural speech, Dr Zhao promised to honor CBA’s tradition, to attract new blood from old and young, to maximize each CBA member’s potential, and to promote in-depth collaboration with biopharmaceutical partners to achieve a greater impact of CBA worldwide.

In his closing remarks, Dr Long expressed his sincere appreciation for the strong support and broad participation of CBA members and friends and for the generous support from the speakers and sponsors, many of which exhibited and showcased their products during the conference. 

About the Chinese Biopharmaceutical Association - USA

The Chinese Biopharmaceutical Association – USA (CBA) is one of the largest Chinese American professional associations in the United States.  Founded in 1995, CBA is an independent, non-political, not for-profit professional organization dedicated to promoting science, technology, and business development in the biopharmaceutical fields by fostering research and business collaborations around the world.  The Association is led by its elected board of directors and executive committee.  For more information about the CBA and its programs, visit www.cba-usa.org.

SOURCE Chinese Biopharmaceutical Association

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED